Skip to content
Peptigraph home

Semax

ACTH(4-10) analog. Semax is not FDA approved for any use.

Also called:semax nasal
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusPCAC voted 8–5 for 503A (Jul 2026)Removed from FDA Category 2 on 15 Apr 2026. PCAC voted 8–5 for the 503A list (Jul 2026); not finalized.WADA status unclearFull legal history

Key facts

Class
ACTH(4-10) analog
Also called
semax nasal
Vial sizes sold
5 mg, 10 mg, 30 mg
Community-reported sizes
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)
FDA status
Not approved
Off Category 2, 15 Apr 2026
PCAC vote
8–5 for 503A
Jul 2026, not final
WADA
Unclear
Not named on the 2026 list
Everything on Semax

Semax guides

Vial and dose sizes

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Semax: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
ADHD101No graded study for this goal
Cognition13538Human RCT evidence, 4 of 4Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2018, PMID 29798983
Depression061Animal evidence, 2 of 4European journal of pharmacology 2024, PMID 39442746

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

A synthetic ACTH(4-10) analogue

Semax is a synthetic analogue of the ACTH(4-10) fragment.[12]

In rats, 0.093% of the radioactivity per gram was in the brain 2 min after intranasal dosing, and 80% of it was intact Semax. The abstract reports rapid enzymatic degradation.[14]

Human studies: ulcer, stroke, imaging and EEG

In a peptic ulcer trial, healing at day 14 was seen in 89.5% on intranasal Semax against 30.8% in the control group.[15]

In patients after ischemic stroke, Semax increased plasma BDNF levels regardless of the timing of rehabilitation, and the levels stayed high through the study.[6]

In healthy volunteers, resting-state fMRI after intranasal Semax or placebo found a greater volume of one default-mode-network subcomponent (medial frontal cortex) in the Semax group. The abstract reports no behavioural outcome.[16]

A follow-up of patients with posthypoxic encephalopathy reported EEG episodes of paroxysmal activity in some cases after injection. The authors say the first injection should be given with monitoring of the brain's bioelectric activity.[17]

Regulatory path

Drugs@FDA lists no Semax product.[4]

In FDA's bulks-list notice as archived in April 2026, Semax was removed from category 2 because the nominations were withdrawn. FDA said it intended to consult its advisory committee on July 24, 2026, about including Semax acetate and Semax free base.[5]

Compared with

Common stacks

Semax is often sold pre-mixed or combined with other peptides. A few of these pairs appear together in published studies; each stack page lists what was tested, and the pages below cover the math and what each part has been studied for.

Common questions

Is Semax FDA approved?

No. Semax is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026. Its advisory committee voted 8–5 in July 2026 to add it to the 503A compounding list. That vote is not final.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is Semax?

A synthetic analogue of the ACTH(4-10) fragment.[12]

How does Semax work?

In rats, intranasal Semax reduced the severity of behavioural disturbances caused by the neurotoxin MPTP. The cached papers do not establish a human mechanism.[18]

Is there a Semax nasal spray?

Human studies gave Semax intranasally; the peptic ulcer trial used a 1% solution.[15]

Sources

  1. 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  3. 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  4. 4United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "semax" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  5. 5US compounding: Semax was removed from FDA's 503A category 2 after the nominators withdrew; FDA announced a PCAC consultation on 24 July 2026.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  6. 6[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018PMID 29798983Accessed 2 Oct 2026
  7. 7PubMed search: semax[tiab] (208 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: semax[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (selank[tiab] OR semax[tiab]) AND (randomized[tiab] OR patients[tiab] OR clinical[tiab]) (48 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  11. 11FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  12. 12Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress.European journal of pharmacology · 2024PMID 39442746Accessed 2 Oct 2026
  13. 13PubMed search: semax[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  14. 14[Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration].Bioorganicheskaia khimiia · 2006PMID 16523722Accessed 2 Oct 2026
  15. 15Therapy of peptic ulcer with semax peptide.Bulletin of experimental biology and medicine · 2002PMID 12459874Accessed 2 Oct 2026
  16. 16Effects of Semax on the Default Mode Network of the Brain.Bulletin of experimental biology and medicine · 2018PMID 30225715Accessed 2 Oct 2026
  17. 17[Use of semax at a follow-up of patients with posthypoxic encephalopathy].Anesteziologiia i reanimatologiia · 1999PMID 10199046Accessed 2 Oct 2026
  18. 18The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system.Neuroscience and behavioral physiology · 2004PMID 15341218Accessed 2 Oct 2026

Found an error? Report a correction.